Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Empagliflozin on Cardiac-renal Injury in Patients With Acute ST-segment-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention.

NCT03591991 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT03591991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Empagliflozin on Cardiac-renal Injury in Patients With Acute ST-segment-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention.
Lead sponsor
Chinese PLA General Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
October 1, 2018
Completion date
September 1, 2019
Enrollment
128 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

reperfusion injury, myocardial